Sternberg C.N., de Bono J.S., Chi K.N., Fizazi K., Mulders P., Cerbone L., Hirmand M., Forer D., Scher H.I.
Annals of Oncology 2014 25:2 (429-434) Article Number mdt571
Background: The randomized, double-blind phase III AFFIRM trial demonstrated that enzalutamide, an oral androgen receptor inhibitor, significantly prolonged overall survival (OS) [median 18.4 versus 13.6 months (hazard ratio, HR) 0.63 (95% confidence interval, CI, 0.53-0.75); P < 0.001] compared with placebo in patients with metastatic castration-resistant prostate cancer who received prior docetaxel chemotherapy. Patients and methods: A post hoc analysis was carried out to assess the efficacy and safety of enzalutamide on outcomes in younger (<75 years) and elderly (?75 years) patients in the AFFIRM population. Statistics are presented by age group (<75 years, ?75 years) for efficacy outcomes of OS, radiographic progression-free survival (rPFS), time to prostatespecific antigen (PSA) progression, PSA response, and safety… (ver más)